Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources
News and Community
About us

GlaxoSmithKline Australia Pty Ltd

Regulatory activities for this sponsor.

Loading...

Cancellation by sponsor (234) Cancellation by sponsor (234)
ARTG (112) ARTG (112)
Australian Public Assessment Report (AusPAR) (41)
Prescription medicine registration (19)
Designation or determination (5) Designation or determination (5)
Prescription medicine decision summary (3)
Prescription medicine evaluation (3) Prescription medicine evaluation (3)
Face mask cancellation (1) Face mask cancellation (1)

2025 (10) 2025 (10)
2024 (15) 2024 (15)
2023 (18) 2023 (18)
2022 (61) 2022 (61)
2021 (12) 2021 (12)
2020 (59) 2020 (59)
2019 (31) 2019 (31)
2018 (27) 2018 (27)
2017 (24) 2017 (24)
2016 (11) 2016 (11)
2015 (51) 2015 (51)
2014 (21) 2014 (21)
2013 (9) 2013 (9)
2012 (6) 2012 (6)
2011 (4) 2011 (4)
2010 (7) 2010 (7)
2009 (3) 2009 (3)
2008 (6) 2008 (6)
2007 (6) 2007 (6)
2006 (3) 2006 (3)
2005 (4) 2005 (4)
2004 (1) 2004 (1)
2003 (3) 2003 (3)
2002 (1) 2002 (1)
2001 (1) 2001 (1)
2000 (3) 2000 (3)
1999 (4) 1999 (4)
1998 (5) 1998 (5)
1997 (4) 1997 (4)
1995 (1) 1995 (1)
1991 (6) 1991 (6)

Search

Sponsor content

418 result(s) found, displaying 51 to 60

VENTOLIN RESPIRATOR SOLUTION salbutamol 5mg/mL (as sulfate) inhalation bottle Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
AXOTIDE ACCUHALER fluticasone propionate 500 micrograms powder for inhalation blister pack Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
AIRZATE MDI 250/25 fluticasone propionate 250 microgram/salmeterol (as xinafoate) 25 microgram inhalation - pressurised aerosol can - metered dose Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
AIRZATE MDI 125/25 fluticasone propionate 125 microgram/salmeterol (as xinafoate) 25 microgram inhalation - pressurised aerosol can - metered dose Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
AIRZATE MDI 50/25 fluticasone propionate 50 microgram/salmeterol (as xinafoate) 25 microgram inhalation - pressurised aerosol can - metered dose Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
PAVTIDE MDI 250/25 fluticasone propionate 250 microgram/salmeterol (as xinafoate) 25 microgram inhalation - pressurised aerosol can - metered dose Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
PAVTIDE MDI 125/25 fluticasone propionate 125 microgram/salmeterol (as xinafoate) 25 microgram inhalation - pressurised aerosol can - metered dose Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
PAVTIDE MDI 50/25 fluticasone propionate 50 microgram/salmeterol (as xinafoate) 25 microgram inhalation - pressurised aerosol can - metered dose Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
INFANRIX diphtheria toxoid / pertactin / pertussis filamentous haemagglutinin / pertussis toxoid / tetanus toxoid 0.5mL injection vial Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd
HAVRIX JUNIOR inactivated hepatitis A vaccine 720 ELISA units/0.5mL injection vial Cancelled under Section 30(1)(c) of the Act

17 November 2022

Cancellation by sponsor

Requested by GlaxoSmithKline Australia Pty Ltd

Pages

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Page 10
…
Next page
Last page

Is there anything wrong with this page?

Help us improve this page

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control - external site
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook - external site
(formerly Twitter) - external site
Youtube - external site
Instagram - external site
LinkedIn - external site

Help us improve

We are always looking for ways to improve our website.

Provide feedback - external site

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

GlaxoSmithKline Australia Pty Ltd

Type

Date

Help us improve this page